<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04523883</url>
  </required_header>
  <id_info>
    <org_study_id>2020HNRT03</org_study_id>
    <nct_id>NCT04523883</nct_id>
  </id_info>
  <brief_title>Concurrent Immunotherapy With Postoperative Radiotherapy in Intermediate/High Risk HNSCC Patients Unfit for Cisplatin: The IMPORT Study (IMPORT)</brief_title>
  <acronym>IMPORT</acronym>
  <official_title>Randomized Phase II Trial of Postoperative Radiotherapy With Concurrent JS001（PD-1 Antibody） vs. Postoperative Radiotherapy Alone in Intermediate/High-risk Head and Neck Cancer Patients With a Contraindication to Cisplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eye &amp; ENT Hospital of Fudan University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tianjin Medical University Cancer Institute and Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Fujian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Guizhou Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central South University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate weather concurrent JS001 with postoperative radiotherapy would have survival&#xD;
      benefit in intermediate/high Risk HNSCC Patients who cannot take cisplatin&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 10, 2020</start_date>
  <completion_date type="Anticipated">August 9, 2024</completion_date>
  <primary_completion_date type="Anticipated">August 9, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>from date of enrollment until date of first documented disease progression or death from any cause, assessed up to 2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from date of enrollment until death from any cause, assessed up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related acute toxicity as assessed weekly by CTCAE v4.0 during the course of treatment</measure>
    <time_frame>up to 3 months after completion of radiotherapy</time_frame>
    <description>Acute toxicity profiles, graded according to the NCI CTCAE version 4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related late toxicity as assessed by CTCAE v4.0</measure>
    <time_frame>from 3 months after completion of radiotherapy up to 2 years</time_frame>
    <description>Late toxicity profiles, graded according to the NCI CTCAE version 4.0</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">316</enrollment>
  <condition>Head and Neck Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>concurrent PD-1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent Immunotherapy With Postoperative Radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Postoperative Radiotherapy alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>postoperative radiotherapy</intervention_name>
    <description>postoperative radiotherapy with a dose of 60-66Gy</description>
    <arm_group_label>Radiotherapy alone</arm_group_label>
    <arm_group_label>concurrent PD-1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>JS001</intervention_name>
    <description>JS001 240mg every three week</description>
    <arm_group_label>concurrent PD-1</arm_group_label>
    <other_name>Toripalimab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  1. Histologically confirmed squamous cell carcinoma of the head and neck.Site of tumor&#xD;
             origin in the oral cavity, oropharynx, larynx, hypopharynx , or sinuses (excluding&#xD;
             nasopharynx) 2. With at least one risk factors after radical surgery ①positive margin;&#xD;
             ②close margin（&lt;5mm); ③ENE;④PNI;⑤LVI; ⑤ pT3-4/N2-3( AJCC 8th).⑥ Level IV/V lymph node&#xD;
             metastases for OPC or OC.&#xD;
&#xD;
             3. Have at least one contraindication to cisplatin as defined:&#xD;
&#xD;
             ① Age&gt;65 years old; ②Creatinine clearance (CC) &gt; 30 and &lt; 60 cc/min For this&#xD;
             calculation, use the Cockroft-Gault formula: CC = 0.85 (if female)* ((140-Age) /&#xD;
             (Serum Creatinine)) * (Weight in kg / 72); ③ Zubrod performance status 2;&#xD;
             ④Pre-existing peripheral neuropathy grade ≥ 1; ⑤History of hearing loss, defined as&#xD;
             either: ▪ Existing need of a hearing aid OR ≥ 25 decibel shift over 2 contiguous&#xD;
             frequencies on a pretreatment hearing test as clinically indicated.&#xD;
&#xD;
             4. No distant metastases 5. No synchronous or concurrent head and neck primary tumors&#xD;
             6. ECOG PS 0-2 7. Adequate organ function including the following:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) &gt;= 1.5 * 10^9/l&#xD;
&#xD;
               2. Platelets count &gt;= 80 * 10^9/l&#xD;
&#xD;
               3. Hemoglobin &gt;= 80 g/dl&#xD;
&#xD;
               4. AST and ALT &lt;= 2.5 times institutional upper limit of normal (ULN)&#xD;
&#xD;
               5. Total bilirubin &lt;= 1.5 times institutional ULN&#xD;
&#xD;
               6. Creatinine clearance &gt;30 ml/min 8. Signed written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior chemotherapy or anti-cancer biologic therapy for any type of cancer, or prior&#xD;
             radiotherapy to the head and neck region&#xD;
&#xD;
          2. Other previous cancer, except for in situ cervical cancer and cutaneous basal cell&#xD;
             carcinoma&#xD;
&#xD;
          3. Pregnant or breast-feeding females, or females and males of childbearing potential not&#xD;
             taking adequate contraceptive measures&#xD;
&#xD;
          4. Uncontrolled concomitant illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac&#xD;
             arrhythmia&#xD;
&#xD;
          5. Active, known or suspected autoimmune disease such as interstitial pneumonia, uveitis,&#xD;
             Crohn's disease, autoimmune thyroiditis. Subjects with cured childhood asthma, type I&#xD;
             diabetes mellitus and hypothyroidism only requiring hormone replacement, or skin&#xD;
             disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment&#xD;
&#xD;
          6. Using systemic immunosuppressive agents and continue the dose within 2 weeks prior to&#xD;
             the enrollment;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shengjin Dou</last_name>
    <phone>15800386875</phone>
    <email>doushengjin@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guopei Zhu</name>
      <address>
        <city>Shanghai</city>
        <zip>200011</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shengjin Dou</last_name>
      <phone>15800386875</phone>
      <email>doushengjin@126.com</email>
    </contact>
    <investigator>
      <last_name>Guopei Zhu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2020</study_first_posted>
  <last_update_submitted>April 12, 2021</last_update_submitted>
  <last_update_submitted_qc>April 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Head and neck cancer</keyword>
  <keyword>radiotherapy</keyword>
  <keyword>PD-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

